论文部分内容阅读
本研究旨在探讨吲哚胺2,3-二氧化酶(IDO)在白血病细胞中的表达和作用。应用间接免疫荧光染色光法检测人急性单核细胞白血病(M5)和急性淋巴细胞白血病(ALL)的细胞内吲哚胺2,3-二氧化酶的表达情况,并以小鼠急性淋巴细胞白血病细胞系L1210建立白血病小鼠模型以观察吲哚胺2,3-二氧化酶抑制剂1-甲基色氨酸是否具有抑制白血病细胞生长的作用。结果表明:M5和ALL的白血病细胞中吲哚胺2,3-二氧化酶阳性细胞率分别为29.4±11.2%和24.7±7.96%,而对照组的外周血单个核细胞中吲哚胺2,3-二氧化酶阳性细胞率仅为3±1.2%;两个白血病组与正常对照组在吲哚胺2,3-二氧化酶阳性细胞率方面的差异均有显著的统计学意义(P<0.05),而M5与ALL组之间在吲哚胺2,3-二氧化酶阳性细胞率方面无显著性差异(P>0.05);1-甲基色氨酸(1-MT)治疗的白血病小鼠与对照组比较,肿瘤消退,生存期延长(P<0.05),部分治疗小鼠达到无病长期生存(注射肿瘤细胞后生存期超过3个月)。结论:人急性单核细胞白血病(M5)和急性淋巴细胞白血病(ALL)的细胞均表达吲哚胺2,3-二氧化酶,1-甲基色氨酸对白血病小鼠有一定的治疗作用。
This study aimed to investigate the expression and role of indoleamine 2,3-dioxygenase (IDO) in leukemia cells. The expression of indoleamine 2,3-dioxygenase in human acute monocytic leukemia (M5) and acute lymphoblastic leukemia (ALL) was detected by indirect immunofluorescence staining and the expression of indoleamine 2,3-dioxygenase in mouse acute lymphoblastic leukemia Cell Line L1210 A leukemia mouse model was established to observe whether 1-methyltryptophan, an indoleamine 2,3-dioxide inhibitor, has the effect of inhibiting the growth of leukemia cells. The results showed that the positive rates of indoleamine 2,3-dioxygenase in leukemia cells of M5 and ALL were 29.4 ± 11.2% and 24.7 ± 7.96%, respectively. In the control group, the levels of indoleamine 2, 3-dioxygenase-positive cell rate was only 3 ± 1.2%; two leukemia group and the normal control group indole amine 2,3-dioxide-positive cell rate differences were statistically significant (P < 0.05). There was no significant difference in the rate of indoleamine 2,3-dioxygenase-positive cells between M5 and ALL groups (P> 0.05), while 1-methyltryptophan (1-MT) Compared with the control group, the tumor subsided and the survival time prolonged (P <0.05). Some mice in the treatment group achieved disease-free long-term survival (tumor cells survived more than 3 months after injection). CONCLUSION: Indoleamine 2,3-dioxygenase and 1-methyltryptophan are all effective in the treatment of leukemia mice in human acute monocytic leukemia (M5) and acute lymphoblastic leukemia (ALL) cells .